Participated · Series B · Jan 2026

Vista AI provides an AI-driven cardiac MRI automation platform that allows technologists of any experience level to consistently acquire high-quality scans. Its software, already FDA-cleared and commercially deployed, has enabled hospitals such as Brigham and Women’s to open 50 % more scan slots and eliminate a 28-day backlog, while cutting scan times by more than 50 % at Radiology Regional. Headquartered in Palo Alto, the company plans to extend its technology to brain, prostate, and spine imaging, pending additional FDA clearances, and to offer remote scanning services so facilities without in-house experts can perform advanced MRI exams. These expansions aim to create the first comprehensive, fully automated MRI platform and to mitigate the industry’s acute technologist shortage. Vista AI is backed by leading venture funds and prominent U.S. health systems. Following its latest raise, the firm intends to accelerate product development, broaden clinical adoption, and deepen its presence across health networks. The company’s momentum underscores strong demand for solutions that standardize imaging quality while expanding patient access.

Participated · Equity · Jun 2025

Visby Medical is an infectious-disease diagnostics company whose flagship product is a disposable, handheld Personal PCR platform that produces sample-to-result answers in less than 30 minutes. The device has already secured FDA Emergency Use Authorization for use in moderate-complexity CLIA laboratories and is engineered for future point-of-care and over-the-counter settings. By eliminating the need for sample transport and central-lab processing, Visby aims to decentralize testing and speed clinical decision making. In October 2020 the company received Phase 2 funding from the NIH’s Rapid Acceleration of Diagnostics (RADx) program, validating both the technology and its potential impact on national testing capacity. Management plans to apply the funds toward high-volume production lines, supplier-base security, and manufacturing automation so it can meet growing demand. Visby is also working with government and private partners to expedite deployment of its COVID-19 test and expand its diagnostic menu over time. Although exact revenue or unit shipment figures were not disclosed, the funding underscores Visby’s move from pilot manufacturing to large-scale commercialization.

Participated · Series A · Nov 2024

OneCell Diagnostics develops an in-house blood-based biopsy test (OncoIndx Ikon) that captures circulating tumor cells from a 10 ml blood draw and combines CTC DNA with RNA and cell-surface protein testing in a True-Single-Cell-Multi-omics workflow. It uses a proprietary antibody-coated glass bead to filter CTCs and applies AI/ML via its iCare app to help oncologists interpret results. The company provides pan-cancer analysis for solid tumors and deliberately targets recurrence patients rather than first-time diagnoses because of regulatory constraints in the U.S. OneCell has served nearly 10,000 patients in India, works with major Indian hospitals and academic partners, and says its offering is roughly one-fifth the price of competitors. The startup has offices in Mumbai, a lab in Pune, a Silicon Valley R&D presence and a headcount of about 144 (120 in India and 24 in the U.S.). It plans to use its India data and analytics to launch and scale in the U.S., projecting outreach to over 1,000 oncologists and one million patients in the near term. Financially, it recently closed a $16 million Series A to fund U.S. expansion and further scaling in India.

Participated · Equity · Jan 2023

Censinet offers Censinet RiskOps, a cloud-based, HIPAA-secure risk exchange that automates third-party and enterprise risk-management workflows for providers, payers, and vendors. Its platform includes a Digital Risk Catalog of over 34,000 vendors and products, automated corrective action plans, real-time portfolio management, and Board-ready reporting. The company reports close to 40 customers, 100% ARR growth year-over-year through Q3 2022, and says it has never lost a customer. Censinet recently launched a Healthcare Cybersecurity Benchmarking Study co-sponsored by the American Hospital Association and KLAS Research. The new funding is earmarked for sales and marketing, product development, and customer success to expand the customer base, drive ACV expansion via new product modules, and enter adjacent markets and verticals. Censinet is based in Boston, MA. Censinet offers the Censinet Platform, described as the first third-party risk management platform built by and for healthcare providers to manage vendor threats to patient care. The platform includes One-click Assessment capabilities and a Digital Vendor Catalog that the company says reduce vendor risk assessment time from weeks to seconds, automate workflows, and provide continuous real-time vendor risk insights. Censinet maintains an advisory board of C-level executives from top-tier healthcare providers and vendors who served as design partners during product development. The company announced the launch of the Censinet Platform in April 2019 and emphasizes a security-first approach targeted at healthcare CIOs and CISOs. Censinet intends to use recent funding to expand the platform’s vendor risk management capabilities, scale its go-to-market team, and accelerate adoption by healthcare providers and their vendors. Censinet is led by CEO and Founder Ed Gaudet and is based in Boston, MA.

Participated · Series B · Oct 2022

Vita Therapeutics develops iPSC-based cellular therapeutics aimed at repairing and replacing defective muscle cells and creating cancer immunotherapies. Its lead programs include VTA-100 for LGMD2A (in IND-enabling studies), VTA-120 for FSHD, and VTA-300, a CAR-based cancer immunotherapy. VTA-100 and VTA-120 are designed as autologous treatments combining gene correction with iPSC technology; the company intends to pursue a dual strategy beginning with autologous cells and later moving to a universal hypoimmunogenic cell line. Vita is working with partners including PanCella, the Wyss Institute, and Johns Hopkins University to advance its programs. The company aims to file Investigational New Drug applications for VTA-100 within the next 18 months. Financially, Vita completed a $31 million Series B and has raised $66 million since inception. Vita Therapeutics is a cell engineering company that uses induced pluripotent stem cell (iPSC) technology and genetic engineering to develop autologous and universal hypoimmunogenic cellular therapies for muscular dystrophies. Its lead program, VTA-100, combines gene correction with iPSC-derived muscle stem cells and is undergoing IND-enabling studies for limb-girdle muscular dystrophy (LGMD) 2A/R1. A second program, VTA-200, is a genetically engineered hypoimmunogenic iPSC-derived treatment intended to address multiple muscular dystrophies, and the company is also developing VTA-300 (cell type undisclosed). Vita plans to complete IND-enabling studies for VTA-100, submit an IND to the FDA, manufacture cells for clinical evaluation, and recruit patients for its first trial. The company follows a dual manufacturing strategy—starting autologously before moving to a universal hypoimmunogenic cell line—and was founded in 2019 out of Johns Hopkins University and the Kennedy Krieger Institute. Vita is a Cambrian Biopharma affiliate and is based in Baltimore, Maryland. The oversubscribed $32 million Series A will fund completion of IND-enabling work, cell manufacturing, patient recruitment, and further development of VTA-200 and VTA-300.